ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) named Weihai He as chief business officer effective Monday, a Tuesday Hong Kong bourse filing said.
From 2021 to 2025, He served on the board of supervisors of the Global Health Drug Discovery Institute and a deputy director of business development and licensing at Bill and Melinda Gates Foundation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.